Sellas Life Sciences: A Survival Win, a $172.5 Million Raise, and the Filing Still to Come
Published on 11/21/2026 at 15:21 | Editorial boerse-global.deSellas Life Sciences closed its share placement on Friday, including the fully exercised greenshoe option, for gross proceeds of $172.5 million. The offering was priced at $13.00 per share, a discount to the market, and the stock fell 8.1% as the capital raise weighed on the quote.
Roughly 13.3 million shares were placed in total. The gross figure is not a net inflow — underwriting discounts, commissions and other expenses still come out of it, and it is a separate item from the company's reported cash position.
What REGAL actually showed
The clinical news that preceded the financing came on November 17, when Sellas reported positive results from the Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia. The study met its primary endpoint on overall survival. Median overall survival came in at 24.0 months on galinpepimut-S against 14.7 months on the best available treatment.
The company put the hazard ratio at 0.59 and the p-value at 0.035, and reported a 41% reduction in the risk of death compared with the best available treatment. Those figures are the factual core of the investment case — they describe the comparison between treatment arms on the pre-specified endpoint, and they are not the same thing as a regulatory decision. Clinical result, regulatory pathway and financing are three distinct layers, and anyone assessing the stock should keep them apart.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
From endpoint to application
Sellas intends to meet with the US Food and Drug Administration to discuss an accelerated submission strategy and to prepare a biologics license application. The company names the first half of 2027 as its target for filing. That is a plan, not a submission already made — a distinction that determines what investors should now measure the story against. The key question shifts from whether the endpoint could be reached to whether the regulatory plan can be executed.
A second clinical thread runs alongside it. In its third-quarter 2026 report on November 12, Sellas cited 40 enrolled patients in the Phase 2 study of SLS009 in newly diagnosed AML in first-line treatment, with preliminary initial results expected in the fourth quarter of 2026. That program is a different agent in a different phase; it adds a further development line rather than confirming the galinpepimut-S data.
Cash before and after
As of September 30, 2026, Sellas reported cash and cash equivalents of $134.7 million — a balance struck before the placement and therefore separate from the gross proceeds announced later. Additional shares mean dilution; additional capital and a successful trial endpoint answer different questions. Fixating on the dilution effect alone would be as short-sighted as extrapolating the trial win indefinitely.
What remains is the transition Sellas has announced: REGAL has delivered the efficacy evidence, and the regulatory execution is the next scheduled step. That execution is where the story now turns.
Ad
Sellas Life Sciences Stock: New Analysis - 21 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
